Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAD in Acute on Chronic Hepatitis
NCT00771446Phase 2Completed
- Sponsor
- Vital Therapies, Inc.
- Start
- Oct 2008
- Primary completion
- Apr 2009
- Modality
- Cell Therapies, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ELAD in acute-on-chronic hepatitis (2 arms), sponsored by Vital Therapies, Inc. Primary endpoints: 30-day transplant-free survival and Safety of ELAD treatment at 12 months. Started Oct 2008; status: completed.
02
Drugs
ELAD
03
Conditions
acute-on-chronic hepatitis
Beyond the preview
Go deeper on NCT00771446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771446.